UMIN-CTR Clinical Trial

UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials


Recruitment status Completed
Unique ID issued by UMIN UMIN000000843
Receipt No. R000000989
Scientific Title A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy(JBCRG-04)
Date of disclosure of the study information 2007/11/01
Last modified on 2019/11/21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments

Basic information
Public title A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy(JBCRG-04)
Acronym JBCRG-04(CREATE-X)
Scientific Title A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy(JBCRG-04)
Scientific Title:Acronym JBCRG-04(CREATE-X)
Japan Asia(except Japan)

Condition Breast cancer
Classification by specialty
Hematology and clinical oncology Breast surgery
Classification by malignancy Malignancy
Genomic information YES

Narrative objectives1 This study is designed to investigate the efficacy and safety of capecitabine, as a postoperative adjuvant chemotherapy, for breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy. In addition, the cost-effectiveness of capecitabine is to be investigated.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase III

Primary outcomes Disease free survival
Key secondary outcomes Overall survival, safety, cost-effectiveness, Time to recurrence, time to death

Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Dynamic allocation YES
Institution consideration Institution is considered as adjustment factor in dynamic allocation.

No. of arms 2
Purpose of intervention Treatment
Type of intervention
Interventions/Control_1 chemotherapy (capecitabine)
Interventions/Control_2 Standard therapy (hormone therapy, radiotherapy)

Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Female
Key inclusion criteria 1. Female patient with primary, infiltrative breast cancer who has been diagnosed on a histological basis.
2. Stage I-IIIB at the first diagnosis and underwent curative resection.
3. The patient was non-pCR after preoperative chemotherapy including anthracycline agents; that is, she had undergone primary tumor resection and pathologically confirmed to have residual cancer cells. The previously adminstered preoperative chemotherapy must have involved at least four cycles of anthracycline agents. However, even if Anthracycline regimen is shorter than 4 courses, the following regimen can be registered.
- FEC 3 courses (EPI>=100mg/m2)+Docetaxel 3 courses
- FEC 3 courses+TC (Docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2) 3 courses
- TC 3 courses+FEC 3 courses
- TC only over 4 courses
4. The patient has been confirmed to be HER2 negative. etc.
5. The patient is aged 20 to 74
6. The patient's general performance status is 0 to 1.
7. The patient must have no carry-over of efficacy from any previous treatment.
8. The patient has maintained sufficient organ function to permit valid evaluation.
9. The patient must have no adverse drug reactions of grade 2 or higher carried over from previous treatment.
10. The ptient's creatinine clearance is higher than 50 mL/min
11. The patient has personally given written, informed consent to participate in this study.
Key exclusion criteria 1. The patient is considered to require postoperative chemotherapy other than capecitabine.
2. The patient has previously been treated with oral 5-FU agents (however, previous treatment with iv 5-FU is acceptable).
3. The patient has either simultaneous or non-simultaneous bilateral breast cancer.
4. The Patients has or has a history of other malignancies or synchronic multiple cancers. However, lesions corresponding to carcinoma in situ or intramucosal carcinoma healed by topical therapy are eligible.
5. The patient is pregnant, has the potential and/or wishes to become pregnant, or is breastfeeding.
6. The patient has previously had an organ transplant.
7. The patient shows hypersensitivity to fluoropyrimidine agents; has previously suffered severe adverse drug reactions with fluoropyrimidine agents; or has a history of serious hypersensitivity to LHRH analogs, tamoxifen, letrozole, anastrozole, and/or exemestane.
8. The patient is currently suffering from serious complications or associated disorders, such as malignant hypertension, congestive heart failure, coronary failure, arrhythmias requiring treatment, infectious diseases, and/or hemorrhagic tendency, and/or has suffered a myocardial infarction within the previous 6 months.
9. The patient has a fever, and there is the possibility that she has an infection.
10. The patient has been shown to have metastasis to other organs.
11. The patient requires treatment for epilepsy and/or central nervous system disorders.
12. The patient is currently being treated for, or has a history of, psychiatric disease.
13. It would be difficult to orally administer drugs to the patient, and/or she suffers from functional insufficiency of the upper gastrointestinal tract and/or malabsorption syndrome.
14. For any other reason, the investigator or sub-investigator has judged the patient to be ineligible for participation.
Target sample size 900

Research contact person
Name of lead principal investigator
1st name Norikzau
Middle name
Last name Masuda
Organization Osaka National Hospital
Division name Department of Surgery (Breast Oncology)
Zip code 540-0006
Address 1-14, 2-chome Hoenzaka, Chuou-ku, Osaka-city, Osaka
TEL 06-6942-1331

Public contact
Name of contact person
1st name Katsumasa
Middle name
Last name Kuroi
Organization JBCRG
Division name Head office
Zip code 103-0016
Address 9-4-3F, Nihonbashikoamicho, Chuo-ku, Tokyo, Japan
TEL 03-6264-8873
Homepage URL

Institute JBCRG (Japan Breast Cancer Research Group)
KBCS(Korean Breast Cancer Society)
KCSG(Korean Cancer Study Group)

Funding Source
Organization ACRO (Advanced Clinical Research Organization),JBCRG (Japan Breast Cancer Research Group)
Category of Funding Organization Self funding
Nationality of Funding Organization Japan

Other related organizations
Name of secondary funder(s)

IRB Contact (For public release)
Organization JBCRG
Address 9-4 Nihonbashikoamicho, Chuo-ku, Tokyo, Japan
Tel 03-6264-8873

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2

Institutions (北海道)北海道大学病院Hokkaido University Hospital/ 北海道がんセンターHokkaido Cancer Center
(青森県)弘前市立病院Hirosaki Municipal Hospital
(岩手県)岩手医科大学附属病院Iwate Medical University
(宮城県)宮城県立がんセンターMiyagi Cancer Center
(群馬県)群馬県立がんセンターGunma Prefectural Cancer Center
(茨城県)土浦協同病院Tsuchiura Kyodo General Hospital
(栃木県)自治医科大学附属病院Jichi Medical University Hospital
(埼玉県)さいたま赤十字病院Saitama Red Cross Hospital
(東京都)多摩総合医療センターTokyo Metropolitan Tama Medical Center/ 東京都立駒込病院Tokyo Metropolitan Komagome Hospital/ 東京共済病院Tokyo Kyosai Hospital/ 国立がんセンター中央病院National Cancer Center Hospital/ 東京慈恵会医科大学附属病院The Jikei University Hospital/ 虎ノ門病院Toranomon Hospital/ 順天堂大学医学部附属順天堂病院Juntendo University Hospital
(神奈川県)東海大学医学部付属病院Tokai University Hospital/ 聖マリアンナ医科大学病院St. Marianna University School of Medicine Hospital/ 神奈川県立がんセンターKanagawa Cancer Center
(石川県)金沢大学医学部附属病院Kanazawa University Hospital
(福井県)福井赤十字病院Fukui Red Cross Hospital
(長野県)信州大学医学部附属病院Shinshu University School of Medicine/ 飯田市立病院Iida Municipal Hospital
(山梨県)山梨県立中央病院Yamanashi Prefectural Central Hospital
(愛知県)愛知県がんセンター中央病院Aichi Cancer Center Hospital/ 名古屋医療センターNagoya Medical Center/ 名古屋市立東部医療センター東市民病院Nagoya City East Medical Center/ 一宮市立市民病院Ichinomiya Municipal Hospital/ 名古屋市立大学病院Nagoya City University Hospital
(京都府) 京都大学医学部附属病院Kyoto University Hospital/ 京都民医連中央Kyoto Miniren Chuo Hospital
(大阪府)大阪医療センターOsaka National Hospital/ 堺市立総合医療センターSakai City Medical Center/ りんくう総合医療センターRinku General Medical Center/ 八尾市立病院Yao Municipal Hospital/大阪労災病院Osaka Rosai Hospital/大阪赤十字病院Osaka Red Cross Hospital/ 大阪警察病院Osaka Police Hospital/大阪市立大学医学部附属病院Osaka City University Hospital/関西医科大学附属枚方病院Kansai Medical University Hirakata Hospital/相原病院Aihara Hospital/ 大阪大学医学部附属病院Osaka University Hospital
(奈良県)市立奈良病院Nara City Hospital/ 奈良県立医科大学付属病院Nara Medical University Hospital
(和歌山県)公立那賀病院Naga Hospital
(兵庫県)兵庫県立がんセンターHyogo Cancer Center/ 兵庫医科大学病院Hyogo College of Medicine
(岡山県)岡山大学病院Okayama University Hospital
(広島県)広島市立安佐市民病院Hiroshima City Asa Citizens Hospital/ 広島市立広島市民病院Hiroshima City Hiroshima Citizens Hospital/ 済生会広島病院Saiseikai Hiroshima Hospital/ JA広島総合病院Hiroshima General Hospital/ 広島大学病院Hiroshima University Hospital/ 県立広島病院Hiroshima Prefectural Hospital
(山口県)山口大学医学部附属病院Yamaguchi University Hospital
(島根県)松江赤十字病院Matsue Red Cross Hospital
(愛媛県)四国がんセンターShikoku Cancer Center
(福岡県)九州がんセンターNational Hospital Organization Kyushu Cancer Center
(熊本県)熊本市立熊本市民病院Kumamoto City Hospital
(大分県)別府医療センターBeppu Medical Center
(鹿児島県)博愛会相良病院Social Medical Corporation Hakuaikai, Sagara Hospital
(沖縄県)中頭病院Nakagami Hospital
Samsung Medical Center
Seoul National University Bundang Hospital
Severance Hospital
Asan Medical Center
Yeungnam University Medical Center
National Cancer Center
Korea University Anam Hospital
Ajou University Hospital
Kyungpook National university hospital
Chungbuk National University Hospital
Soonchunhyang University Hospital Bucheon
Inje University Busan Paik hospital
Gangnam Severance Hospital
Hallym University Kangdong Sacred Heart Hospital
Gangneung Asan Hospital
Inha University Hospital
Seoul National University Hospital
Ewha Womans University Mokdong Hospital
Hallym University Sacred Heart Hospital
Konkuk University Medical Center
Soonchunhyang University Hospital Cheonan
Inje University Sanggye Paik Hospital

Other administrative information
Date of disclosure of the study information
2007 Year 11 Month 01 Day

Related information
URL releasing protocol N/A
Publication of results Published

URL related to results and publications N/A
Number of participants that the trial has enrolled 610
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Recruitment status Completed
Date of protocol fixation
2006 Year 10 Month 18 Day
Date of IRB
2006 Year 11 Month 28 Day
Anticipated trial start date
2007 Year 02 Month 01 Day
Last follow-up date
2015 Year 09 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other related information

Management information
Registered date
2007 Year 10 Month 06 Day
Last modified on
2019 Year 11 Month 21 Day

Link to view the page

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name

Contact us.